Nieves Martinez Lago, Consultant Medical Oncologist at University Hospital Complex of Santiago de Compostela, shared a post on X:
“Peg-GCSF Primary Prophylaxis in mFOLFIRINOX for Pancreatic Cancer
- Randomized phase II trial
- Peg-GCSF cut grade 3–4 neutropenia 2.6% vs 38.5%
- FN only in control arm (12.8%)
- Trend to better survival + improved QoL
- No increase in bone pain.”
More posts about Pancreatic Cancer.